Our study revealed the molecular mechanism of interrelation between HIF‐1α and EZH2 and provides a pharmacological basis for the dual targeting of HIF‐1α and EZH2, and the dual‐targeting compound DYB‐03 may be a promising candidate for the treatment of various cancer, such as lung cancer. Here, EZH2 is linked to lung carcinoma.